Serum levels of brain-derived neurotrophic factor at 4 weeks and response to treatment with SSRIs

Psychiatry Investigation

Volumn 11, Issue 1, 2014, Pages 84-88

  Yoshimura, Reiji ^a   Kishi, Taro ^b,c   Hori, Hikaru ^a   Katsuki, Asuka ^a   Sugita Ikenouchi, Atsuko ^a   Umene Nakano, Wakako ^a   Atake, Kiyokazu ^a   Iwata, Nakao ^c   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brain derived neurotrophic factor; Depression; Response; Selective serotonin reuptake inhibitor; Serum

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; DRUG RESPONSE; DSM-IV-TR; FEMALE; HAMILTON SCALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; TREATMENT RESPONSE;

EID: 84893276637     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2014.11.1.84     Document Type: Article

References (21)

1. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006;67:1836-1855.
2. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
3. Katz MM, Meyers AL, Prakash A, Gaynor PJ, Houston JP. Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull 2009;42:94-107.
4. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007;10:1089-1093.
5. Duman RS, Heinger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
6. Sen D, Duman RS, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527-532.
7. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010;11: 763-773.
8. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmmacol 2008;11:1169-1180.
9. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2010;16:1088-1095.
10. Katsuki A, Yoshimura R, Kishi T, Hori H, Umene-Nakano W, Ikenouchi-Sugita A, et al. Serum brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectr 2012;17:155-163.
11. Yoshimura R, Mitoma M, Sugita A, Hori H, Okamoto T, Umene W, et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. ProgNeuropsychopharmacol Biol Psychiatry 2007;31:1034-1037.
12. Umene-Nakano W, Yoshimura R, Ueda N, Suzuki A, Ikenouchi-Sugita A, Hori H, et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol 2010;24:1764-1771.
13. Wolkowitz OM, Wolf J, Shelly W, Rosser R, Burke HM, Lerner G, et al. Serum BDNF levels before treatment predict SSRI response in depression. Prog Neuropsychopharmacol Biol Psychiatyry 2011;35:1623-1630.
14. Tadic A, Wagner S, Schlicht KF, Peetz D, Boysenko L, Dreimuller N, et al. The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study. Prog Neuropsychopharmacol Biol Psychiatyry 2011;35:415-420.
15. American Psychiatric Association. A Text Revision of Diagnostic and Statistical Manual of Mental Disorder. 4th Edition. Washington, DC: American Psychiatric Association; 2000.
16. Dreimuller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C, et al. Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with major depression. Neuropharmacology 2012;62:264-269.
17. Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J, et al. Determinations of serum brain-derived neurotrophic factor. Psychoendocrinology 2011;36:228-239.
18. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002;328:261-264.
19. Radka SF, Holst PA, Frische M, Alter CA. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by sensitive and specific immunoassay. Brain Res 1996;709: 122-301.
20. Lommatzsch M, Zinger D, Schuhbaeck K, Schloetcke C, Zinger C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005;26:115-123.
21. Karege F, Bondolfi G, Gervason N, Schwald M, Aubry JM, Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005;57:1068-1072.